View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

SIRION Biotech

Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development

SIRION Biotech offers custom engineering of viral vectors to improve transduction and performance of in-vitro cell modelling, in-vivo gene modification and therapeutic research and development (R&D).

Am Haag 6,
82166 Graefelfing,
Fax Number
Viral vector systems to improve transduction

SIRION Biotech offers custom engineering of viral vectors to improve transduction and performance of in-vitro cell modelling, in-vivo gene modification and therapeutic research and development (R&D).

The company’s virus-based technologies are used worldwide in academia and industry. SIRION’s strong focus on transduction technologies enables it to offer customisation services for all three major virus types, lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).

Viral vector engineering and manufacture

SIRION engineers and manufactures replication-deficient LV, AAV and AV vectors. The platform offers many add-on options such as inducible expression systems, tissue-specific promoters and specialised transduction boosters for tight expression control.

Custom adeno-associated virus service

SIRION can manufacture a range of AAV serotypes and can engineer these with tissue-specific promotors to increase expression precision of nearly any gene of interest.

SIRION Biotech enables full gene expression control in mammalian cells.
Viral vectors are an ideal tool to shuttle genetic material into mammalian cells.
SIRION Biotech provides custom engineering and production services for lentivirus, adenovirus, and adeno-associated virus (AAV).

Fast protein liquid chromatography (FPLC) grade AAV manufacture techniques provide high-purity products for R&D in less than eight weeks. The sophisticated platform allows the integration of desired expression constructs within the vector’s cloning capacity. Batch sizes range from 5×1011 genetic copies (GC) for small explorative experiments all the way to 5×1014 GC to satisfy complete experimental cohorts.

Additional in-house features of the SIRION AAV technology platform include capsid modifications to target cell-specific transduction. All projects are personally planned with highly trained project managers to ensure resulting vector designs and function fit the client’s intended application.

Custom lentivirus service

SIRION BIOTECH`s custom LV vector service enables the manufacture of constitutive and inducible gene vectors in less than four weeks.

SIRION’s multicistronic vector designs enable customers to create highly homogeneous, stable cell pools, and avoid time-consuming clone selection after transduction.

With the all-in-one inducible vector system, SIRION enables working with difficult cytotoxic genes and knockdown strategies. The manufacture of scales up to 1×109 TU is possible.

Custom adenovirus service

SIRION`s patented BAC technology enables AV construction in less than five weeks.

The system complies with standard safety criteria by using replication-deficient E1/E3 deleted serotype Ad5 as base vector. Desired genes or knockdown expression construct is possible, within a 7.5kb limit.

Transduction enhancers for difficult cell types

SIRION’s in-house developed transduction boosters enable working with difficult-to-transduce cell types such as hematopoietic cells.

The LentiBOOST™ reagent is currently used in several clinical trials to improve genetic modification of hematopoietic stem cells or T-cells for gene-therapy and chimeric antigen receptor T-cell (CAR-T) cell projects.

Developing novel AAV for gene therapy – NextGen AAV

AAVs are heavily utilised in modern gene therapy trials. While standard AAV applications are suitable for pre-clinical target validation and proof-of-principle experiments, they often fall short during the big step into clinical application.

SIRION´s AAV optimisation platform enables you to address AAV limitations before you take that crucial step. All elements of your AAV strategy are considered and optimised with your project’s specific goals in mind.

About SIRION Biotech

SIRION Biotech is a globally active technology provider with a strong customer base in the fields of cancer research, neurosciences, regenerative medicines, gene therapy, CAR T-cell development and R&D of new vaccination methods.

The company was founded in 2007 at the IZB in Martinsried near Munich, Germany. It was designed to shift the paradigm of viral vector technologies and supplies.

Today, the company has more than 500 ongoing projects. SIRION Biotech understands its customers’ technical challenges and offers specialised individual solutions for projects of all sizes.


Maximise your virus uptake with transduction enhancers. Restricted uptake of virus particles often lowers the success of gene or short hairpin ribonucleic acid (shRNA) expression and requires the application of higher viral titers.


SIRION Biotech provides engineered Lentivirus vectors for gene expression and knockdown. Lentivirus vectors are the method of choice whenever a fast, efficient and cost-effective generation of stable cell models is required.


SIRION Biotech’s engineered adenovirus vectors are used for transient and quantitative gene expression or knockdown.

Adeno-associated virus (AAV)

SIRION Biotech provides engineered adeno-associated virus (AAV) vectors for in-vivo gene expression and knockdown experiments, which help uncover the phenotypic impact of a genetic modification on the level of the living organism. AAVs are ideal for this kind of application.


SIRION Biotech offers full customisation services for gene therapy research and development (R&D). The company optimises adeno-associated virus (AAV) tissue specificity and immunogenic profiles.

PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

24 June 2021

Webinar: Engineering AAV Lead Vectors for Gene Therapy

The recombinant adeno-associated virus (rAAV) vector design affects not only the duration and localisation of the therapeutic sequence transcription, but also the manufacturing scalability and generation of manufacturing by-products, such as process and product-related impurities, that compromise the safety and efficacy of rAAV vector particles.

25 March 2021

SIRION Biotech, Sanofi Partner to Revolutionise Gene Therapy Treatments

World leader in viral vector-based gene delivery technologies for gene & cell therapy, SIRION Biotech, is pleased to announce that it signed a license and collaboration agreement with global biopharmaceutical company Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors to realise effective gene therapy treatments for human major organ-affecting disorders.

24 February 2021

SIRION Biotech Receives Gold Stevie Award Trophy

SIRION Biotech was thrilled to receive its trophy after winning a Gold Stevie Award at this year's American Business Awards, winning in the category Fastest Growing Company of the Year – Up to 100 Employees, after achieving record growth in the previous year.

28 September 2020

Viral Vector Engineering from SIRION Biotech

SIRION Biotech provides highly advanced viral vector technology, as well as vector manufacturing platforms established from lentiviruses, adenoviruses, and adeno-associated viruses (AAVs).

17 August 2020

SIRION Achieves Gold Stevie Business Award

For its stellar performance during the past financial year, Sirion Biotech GmbH (SIRION), a specialist viral vector supplier, has been awarded a coveted Gold Stevie® American Business Award.

10 August 2020

Key Candidate hAd19a/64 Outperforms Gold-Standard hAd5 as a Vaccine Vehicle

A recent collaboration between University of Copenhagen's associate professor Peter Johannes Holst, his research group, colleagues at Bogor Agricultural University, and Munich-based viral vector company SIRION Biotech demonstrated that key candidate hAd19a/64 can outperform counterpart and gold-standard hAd5 as a vaccine vehicle.

11 September 2018

CAR-T Acknowledged by FDA Committee

Novartis has announced its CAR-T cell therapy CTL019 has been recommended by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC).

27 July 2017

Sirion Biotech Viral Vector Experience

Gene delivery by viral vectors has taken centre stage in the development of gene therapies and immuno-oncologies. It has revolutionised the precision that complex cell models can be realised.

4 July 2017


Am Haag 6
82166 Graefelfing

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology